Comment on 'Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study'

Br J Dermatol. 2024 Mar 15;190(4):596. doi: 10.1093/bjd/ljad529.
No abstract available

Publication types

  • Comment

MeSH terms

  • Adult
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Clinical Trials, Phase IV as Topic
  • Dermatitis, Atopic* / drug therapy
  • Double-Blind Method
  • Humans
  • Randomized Controlled Trials as Topic
  • Sleep

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • dupilumab